RecruitingPhase 1NCT07219940

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

An Open-label and Dose-escalation Phase I Clinical Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of HLA-G-targeted Exosome (SOB100) in Healthy Subjects

Sponsor

Shine-On Biomedical Co., Ltd.

Enrollment

15 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Targeted Therapy Exosome Healthy Subjects

Summary

The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SOB100 for people with exosome, healthy subjects, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.